dc.contributor.author | Bonovas, Stefanos | en |
dc.contributor.author | Nikolopoulos, Georgios K. | en |
dc.contributor.author | Filioussi, K. | en |
dc.contributor.author | Peponi, Evangelia | en |
dc.contributor.author | Bagos, Pantelis G. | en |
dc.contributor.author | Sitaras, N. M. | en |
dc.creator | Bonovas, Stefanos | en |
dc.creator | Nikolopoulos, Georgios K. | en |
dc.creator | Filioussi, K. | en |
dc.creator | Peponi, Evangelia | en |
dc.creator | Bagos, Pantelis G. | en |
dc.creator | Sitaras, N. M. | en |
dc.date.accessioned | 2018-06-22T09:52:39Z | |
dc.date.available | 2018-06-22T09:52:39Z | |
dc.date.issued | 2010 | |
dc.identifier.uri | https://gnosis.library.ucy.ac.cy/handle/7/41445 | |
dc.description.abstract | A growing body of literature suggests that statins may have a chemopreventive potential against melanoma through pleiotropic anti-inflammatory, immunomodulatory, and antiangiogenesis mechanisms. Our aim was to examine this association through a detailed meta-analysis of randomized controlled trials (RCTs). A comprehensive search for trials published up to June 2009 was performed, reviews of each study were conducted and data were abstracted. Prior to meta-analysis, the studies were evaluated for publication bias and heterogeneity. Pooled relative risk estimates (RR) and 95% confidence intervals (CIs) were calculated using the fixed- and the random-effects models. Subgroup and sensitivity analyses were also conducted. Sixteen RCTs of statins for cardiovascular outcomes, involving 62,568 individuals with a mean age of 60 years and an average follow-up of nearly 4.7 years, contributed to the analysis. We found no evidence of publication bias (P = 0.47) or heterogeneity among the studies (P = 0.25). Statin use did not significantly affect the risk of developing melanoma assuming either a fixed- (RR = 0.92, 95% CI: 0.67-1.26), or a random-effects model (RR = 0.92, 95% CI: 0.62-1.36). This neutral effect was further supported by the results of subgroup and sensitivity analyses. Our findings do not support a protective effect of statins against melanoma. © 2009 Springer Science+Business Media B.V. | en |
dc.language.iso | eng | en |
dc.source | European journal of epidemiology | en |
dc.subject | Article | en |
dc.subject | Female | en |
dc.subject | Male | en |
dc.subject | Human | en |
dc.subject | Aged | en |
dc.subject | Humans | en |
dc.subject | Middle aged | en |
dc.subject | Follow up | en |
dc.subject | Clinical trial | en |
dc.subject | Controlled clinical trial | en |
dc.subject | Randomized controlled trial | en |
dc.subject | Statins | en |
dc.subject | Risk reduction | en |
dc.subject | Systematic review | en |
dc.subject | Melanoma | en |
dc.subject | Skin neoplasms | en |
dc.subject | Meta analysis | en |
dc.subject | Risk assessment | en |
dc.subject | Cancer risk | en |
dc.subject | Placebo | en |
dc.subject | Randomized controlled trials as topic | en |
dc.subject | Risk | en |
dc.subject | 3-hydroxy-3-methylglutaryl-coenzyme a reductase inhibitors | en |
dc.subject | Acyl coenzyme a | en |
dc.subject | Atorvastatin | en |
dc.subject | Cancer prevention | en |
dc.subject | Chemoprevention | en |
dc.subject | Fluindostatin | en |
dc.subject | Hydroxymethylglutaryl coenzyme a reductase inhibitor | en |
dc.subject | Mevinolin | en |
dc.subject | Pravastatin | en |
dc.subject | Simvastatin | en |
dc.title | Can statin therapy reduce the risk of melanoma? A meta-analysis of randomized controlled trials | en |
dc.type | info:eu-repo/semantics/article | |
dc.identifier.doi | 10.1007/s10654-009-9396-x | |
dc.description.volume | 25 | |
dc.description.issue | 1 | |
dc.description.startingpage | 29 | |
dc.description.endingpage | 35 | |
dc.author.faculty | Ιατρική Σχολή / Medical School | |
dc.author.department | Ιατρική Σχολή / Medical School | |
dc.type.uhtype | Article | en |
dc.contributor.orcid | Nikolopoulos, Georgios K.[0000-0002-3307-0246] | |
dc.contributor.orcid | Bagos, Pantelis G. [0000-0003-4935-2325] | |
dc.contributor.orcid | Bonovas, Stefanos [0000-0001-6102-6579] | |
dc.gnosis.orcid | 0000-0002-3307-0246 | |
dc.gnosis.orcid | 0000-0003-4935-2325 | |
dc.gnosis.orcid | 0000-0001-6102-6579 | |